Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Musculoskeletal Disorders
Published in: BMC Musculoskeletal Disorders 1/2022

Open Access 01-12-2022 | Osteoarthrosis | Research

Duloxetine in OsteoArthritis (DOA) study: effects of duloxetine on pain and function in end-stage hip and knee OA – a pragmatic enriched randomized controlled trial

Authors: T. Blikman, W. Rienstra, T. M. van Raaij, A. J. ten Hagen, B. Dijkstra, W. P. Zijlstra, S. K. Bulstra, M. Stevens, I. van den Akker-Scheek

Published in: BMC Musculoskeletal Disorders | Issue 1/2022

Login to get access

Abstract

Background

Some osteoarthritis (OA) patients experience inadequate pain relief from analgesics like acetaminophen and nonsteroidal anti-inflammatory drugs. This could be the result of experienced non-nociceptive centralized pain. Placebo-controlled randomized trials (RCT) have proven the effectiveness of duloxetine for OA and several chronic pain conditions where central sensitization (CS) is one of the key underlying pain mechanisms.

Objectives

Assess the efficacy of an 8-week duloxetine treatment compared to usual care in end-stage knee and hip OA patients with a level of centralized pain.

Design

Pragmatic, enriched, open-label RCT.

Methods

Patients were randomized to duloxetine or to care-as-usual. Primary outcome was pain in the index joint, measured with the pain domain of the Knee injury and Osteoarthritis Outcome Score (KOOS) or the Hip disability and Osteoarthritis Outcome Score (HOOS). The intention-to-treat principle was used, with mixed-model repeated measures to analyze the effect.

Results

One hundred eleven patients were randomized. Nearly 44% felt much to very much better after duloxetine usage compared to 0% in the care-as-usual group (p < 0.001). The duloxetine group scored 11.3 points (95%CI: 5.8, 16.8) better on the pain domain of the KOOS/HOOS (p < 0.001). Knee patients improved significantly more than hip patients (18.7 [95%CI: 11.3, 26.1] versus 6.0 [95%CI: − 2.6, 14.5] points better).

Conclusions

Adding duloxetine treatment seems to be beneficial for end-stage knee OA patients with neuropathic-like symptoms (at risk of CS). End stage Hip OA patients seem to be nonresponsive to duloxetine.

Trial registration

Dutch Trial Registry with number NTR 4744 (15/08/2014) and in the EudraCT database with number 2013–004313-41.
Appendix
Available only for authorised users
Literature
1.
Neogi T. The epidemiology and impact of pain in osteoarthritis. Osteoarthr Cartil. 2013;21(9):1145–53.CrossRef
2.
Zhang W, Nuki G, Moskowitz R, Abramson S, Altman R, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartil. 2010;18(4):476–99.CrossRef
3.
Felson DT, Neogi T. "Emerging treatment models in rheumatology: challenges for osteoarthritis trials. Arthritis Rheum. 2018;70(8):1175–81.
4.
5.
Dimitroulas T, Duarte RV, Behura A, Kitas GD, Raphael JH. Neuropathic pain in osteoarthritis: a review of pathophysiological mechanisms and implications for treatment. Semin Arthritis Rheum. 2014;44(2):145–54.PubMedCrossRef
6.
Thakur M, Dickenson AH, Baron R. Osteoarthritis pain: nociceptive or neuropathic? Nat Rev Rheumatol. 2014;10(6):374–80.PubMedCrossRef
7.
8.
Hochman J, Davis A, Elkayam J, Gagliese L, Hawker G. Neuropathic pain symptoms on the modified painDETECT correlate with signs of central sensitization in knee osteoarthritis. Osteoarthr Cartil. 2013;21(9):1236–42.CrossRef
9.
Shigemura T, Ohtori S, Kishida S, Nakamura J, Takeshita M, Takazawa M, et al. Neuropathic pain in patients with osteoarthritis of hip joint. Eur Orthop Traumatol. 2011;2(3–4):73–7.CrossRef
10.
Ohtori S, Orita S, Yamashita M, Ishikawa T, Ito T, Shigemura T, et al. Existence of a neuropathic pain component in patients with osteoarthritis of the knee. Yonsei Med J. 2012;53(4):801–5.PubMedPubMedCentralCrossRef
11.
Hochman J, Gagliese L, Davis A, Hawker G. Neuropathic pain symptoms in a community knee OA cohort. Osteoarthr Cartil. 2011;19(6):647–54.CrossRef
12.
Hochman JR, French MR, Bermingham SL, Hawker GA. The nerve of osteoarthritis pain. Arthritis Care Res. 2010;62(7):1019–23.CrossRef
13.
Aşkın A, Özkan A, Tosun A, Demirdal ÜS, İsnaç F. Quality of life and functional capacity are adversely affected in osteoarthritis patients with neuropathic pain. Kaohsiung J Med Sci. 2017;33(3):152–8.PubMedCrossRef
14.
Moss P, Benson HAE, Will R, Wright A. Patients with knee osteoarthritis who score highly on the PainDETECT questionnaire present with multimodality hyperalgesia, increased pain, and impaired physical function. Clin J Pain. 2018;34(1):15–21.PubMedCrossRef
15.
Dimitroulas T, Duarte RV, Behura A, Kitas GD, Raphael JH. Neuropathic pain in osteoarthritis: a review of pathophysiological mechanisms and implications for treatment. Semin Arthritis Rheum. 2014;44(2):145–54.
16.
Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014;1.
17.
Wang ZY, Shi SY, Li SJ, Chen F, Chen H, Lin HZ, et al. Efficacy and safety of duloxetine on osteoarthritis knee pain: a meta-analysis of randomized controlled trials. Pain Med. 2015;16(7):1373–85.PubMedCrossRef
18.
Moore R, Cai N, Skljarevski V, Tölle T. Duloxetine use in chronic painful conditions–individual patient data responder analysis. Eur J Pain. 2014;18(1):67–75.PubMedCrossRef
19.
Citrome L, Weiss-Citrome A. A systematic review of duloxetine for osteoarthritic pain. Postgrad Med. 2012;124(1):83–93.
20.
Wang G, Bi L, Li X, Li Z, Zhao D, Chen J, et al. Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study. Osteoarthr Cartil. 2017;25(6):832–8.CrossRef
21.
Micca JL, Ruff D, Ahl J, Wohlreich MM. Safety and efficacy of duloxetine treatment in older and younger patients with osteoarthritis knee pain: a post hoc, subgroup analysis of two randomized, placebo-controlled trials. BMC Musculoskelet Disord. 2013;14(1):137.PubMedPubMedCentralCrossRef
22.
Brown JP, Boulay LJ. Clinical experience with duloxetine in the management of chronic musculoskeletal pain. A focus on osteoarthritis of the knee. Ther Adv Musculoskelet Dis. 2013;5(6):291–304.PubMedPubMedCentralCrossRef
23.
Allen K, Bierma-Zeinstra S, Foster N, Golightly Y, Hawker G. OARSI clinical trials recommendations: design and conduct of implementation trials of interventions for osteoarthritis. Osteoarthr Cartil. 2015;23(5):826–38.CrossRef
24.
Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum. 1986;29(8):1039–49.PubMedCrossRef
25.
Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum. 1991;34(5):505–14.PubMedCrossRef
26.
Blikman T, Rienstra W, van Raaij TM, ten Hagen AJ, Dijkstra B, Zijlstra WP, et al. Duloxetine in OsteoArthritis (DOA) study: study protocol of a pragmatic open-label randomised controlled trial assessing the effect of preoperative pain treatment on postoperative outcome after total hip or knee arthroplasty. BMJ Open. 2016;6(3):e010343–2015-010343.CrossRef
27.
Rienstra W, Blikman T, Mensink FB, van Raay JJ, Dijkstra B, Bulstra SK, et al. The modified painDETECT questionnaire for patients with hip or knee osteoarthritis: translation into Dutch, cross-cultural adaptation and reliability assessment. PLoS One. 2015;10(12):e0146117.PubMedPubMedCentralCrossRef
28.
Dunner DL, Wohlreich MM, Mallinckrodt CH, Watkin JG, Fava M. Clinical consequences of initial duloxetine dosing strategies: comparison of 30 and 60 mg QD starting doses. Curr Ther Res. 2005;66(6):522–40.PubMedPubMedCentralCrossRef
29.
30.
31.
Bruggink JW. Levensverwachting zonder chronische ziektes. Statistisch kwartaalblad over de demografie van Nederland. 2011;59(1):43–5.
32.
Lame IE, Peters ML, Kessels AG, Van Kleef M, Patijn J. Test--retest stability of the Pain Catastrophizing Scale and the Tampa Scale for Kinesiophobia in chronic pain over a longer period of time. J Health Psychol. 2008;13(6):820–6.PubMedCrossRef
33.
Crombez G, Vlaeyen JW, Heuts PH, Lysens R. Pain-related fear is more disabling than pain itself: evidence on the role of pain-related fear in chronic back pain disability. Pain. 1999;80(1):329–39.PubMedCrossRef
34.
Crombez G, Eccleston C, Baeyens F, Eelen P. When somatic information threatens, catastrophic thinking enhances attentional interference. Pain. 1998;75(2):187–98.PubMedCrossRef
35.
Spinhoven P, Ormel J, Sloekers P, Kempen G, Speckens A, Av H. A validation study of the hospital anxiety and depression scale (HADS) in different groups of Dutch subjects. Psychol Med. 1997;27(2):363–70.PubMedCrossRef
36.
37.
Roos EM, Roos HP, Lohmander LS, Ekdahl C, Beynnon BD. Knee injury and osteoarthritis outcome score (KOOS)—development of a self-administered outcome measure. J Orthop Sports Phys Ther. 1998;28(2):88–96.PubMedCrossRef
38.
Nilsdotter AK, Lohmander LS, Klassbo M, Roos EM. Hip disability and osteoarthritis outcome score (HOOS)--validity and responsiveness in total hip replacement. BMC Musculoskelet Disord. 2003;4:10.PubMedPubMedCentralCrossRef
39.
de Groot I, Favejee M, Reijman M, Verhaar J, Terwee C. The Dutch version of the knee injury and osteoarthritis outcome score: a validation study. Health Qual Life Outcomes. 2008;6(1):16.PubMedPubMedCentralCrossRef
40.
De Groot I, Reijman M, Terwee C, Bierma-Zeinstra S, Favejee M, Roos E, et al. Validation of the Dutch version of the hip disability and osteoarthritis outcome score. Osteoarthr Cartil. 2007;15(1):104–9.CrossRef
41.
42.
43.
Freynhagen R, Baron R, Gockel U, Tölle TR. Pain DETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22(10):1911–20.PubMedCrossRef
44.
Rienstra W, Blikman T, Dijkstra B, van Raay J, Slager G, Bulstra S, et al. Validity of the Dutch modified painDETECT questionnaire for patients with hip or knee osteoarthritis. Disabil Rehabil. 2019;41(8):941–7.
45.
Arendt-Nielsen L, Nie H, Laursen MB, Laursen BS, Madeleine P, Simonsen OH, et al. Sensitization in patients with painful knee osteoarthritis. Pain. 2010;149(3):573–81.PubMedCrossRef
46.
Wessel J. The reliability and Vatidity of pain threshold measurements in osteoarthritis of the knee. Scand J Rheumatol. 1995;24(4):238–42.PubMedCrossRef
47.
Walton DM, Levesque L, Payne M, Schick J. Clinical pressure pain threshold testing in neck pain: comparing protocols, responsiveness, and association with psychological variables. Phys Ther. 2014;94(6):827–37.PubMedPubMedCentralCrossRef
48.
Rolke R, Baron R, Maier C, Tölle T, Treede R, Beyer A, et al. Quantitative sensory testing in the German research network on neuropathic pain (DFNS): standardized protocol and reference values. Pain. 2006;123(3):231–43.PubMedCrossRef
49.
Suokas A, Walsh D, McWilliams D, Condon L, Moreton B, Wylde V, et al. Quantitative sensory testing in painful osteoarthritis: a systematic review and meta-analysis. Osteoarthr Cartil. 2012;20(10):1075–85.CrossRef
50.
Price DD, McGrath PA, Rafii A, Buckingham B. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain. 1983;17(1):45–56.PubMedCrossRef
51.
Guy W. ECDEU assessment manual for psychopharmacology. In: Anonymous US Department of Health, education, and welfare, public health service, alcohol, drug abuse, and mental health administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976. p. 217–22.
52.
Chappell AS, Ossanna MJ, Liu-Seifert H, Iyengar S, Skljarevski V, Li LC, et al. Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial. Pain. 2009;146(3):253–60.PubMedCrossRef
53.
Skljarevski V, Zhang S, Desaiah D, Alaka KJ, Palacios S, Miazgowski T, et al. Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial. J Pain. 2010;11(12):1282–90.PubMedCrossRef
54.
Chappell AS, Bradley LA, Wiltse C, Detke MJ, D’Souza DN, Spaeth M. A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med. 2008;1:91.PubMedCrossRef
55.
Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain. 2008;136(3):432–44.PubMedCrossRef
56.
Roos EM, Lohmander LS. The knee injury and osteoarthritis outcome score (KOOS): from joint injury to osteoarthritis. Health Qual Life Outcomes. 2003;1:64.PubMedPubMedCentralCrossRef
57.
Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, et al. Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Ann Rheum Dis. 2005;64(1):29–33.PubMedCrossRef
58.
Abou-Raya S, Abou-Raya A, Helmii M. Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial. Age Ageing. 2012;41(5):646–52.PubMedCrossRef
59.
Dabare C, Le Marshall K, Leung A, Page CJ, Choong PF, Lim KK. Differences in presentation, progression and rates of arthroplasty between hip and knee osteoarthritis: observations from an osteoarthritis cohort study-a clear role for conservative management. Int J Rheum Dis. 2017;20(10):1350–60.PubMedPubMedCentralCrossRef
60.
61.
Beswick AD, Wylde V, Gooberman-Hill R, Blom A, Dieppe P. What proportion of patients report long-term pain after total hip or knee replacement for osteoarthritis? A systematic review of prospective studies in unselected patients. BMJ Open. 2012;2(1):e000435.
Metadata
Title
Duloxetine in OsteoArthritis (DOA) study: effects of duloxetine on pain and function in end-stage hip and knee OA – a pragmatic enriched randomized controlled trial
Authors
T. Blikman
W. Rienstra
T. M. van Raaij
A. J. ten Hagen
B. Dijkstra
W. P. Zijlstra
S. K. Bulstra
M. Stevens
I. van den Akker-Scheek
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2022
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/s12891-022-05034-0

Other articles of this Issue 1/2022

BMC Musculoskeletal Disorders 1/2022 Go to the issue

Research

Does obesity affect patient-reported outcomes following total knee arthroplasty?

Research

Sustained improvements in EQ-5D utility scores and self-rated health status in patients with ankylosing spondylitis after spa treatment including low-dose radon – an analysis of prospective radon indication registry data

Research

The role of point-of-Care Musculoskeletal Ultrasound for Routine Joint evaluation and management in the Hemophilia Clinic - A Real World Experience

Research article

The anatomical features of the lateral femoral cutaneous nerve with total hip arthroplasty: a comparative study of direct anterior and anterolateral supine approaches

Research

Does musculoskeletal pain interfere with motor learning in a gait adaptation task? A proof-of-concept study

Research

A scoping review on the methods of assessment and role of resilience on function and movement-evoked pain when experiencing a musculoskeletal injury